OCGN Reports $100M Revenue, $0.05 EPS, Advances OCU400 Phase 3 Data 2027, OCU410ST Phase 2/3 2026, $500M Licensing Deal
Ocugen, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.37
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS